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Abstract
Cardiorenal syndrome (CRS) type 3 is a subclassification of the CRS whereby an episode 
of acute kidney injury (AKI) precipitates and contributes to the development of acute car-
diac injury. There is limited understanding of the pathophysiologic mechanisms of how 
AKI contributes to acute cardiac injury and/or dysfunction. An episode of AKI may have 
effects that depend on the severity and duration of AKI and that both directly and indi-
rectly predispose to an acute cardiac event. Moreover, baseline susceptibility will modify 
the subsequent risk for cardiac events associated with AKI. Experimental data suggest 
cardiac injury may be directly induced by inflammatory mediators, oxidative stress, apop-
tosis and activation of neuroendocrine systems early after AKI. Likewise, AKI may be as-
sociated with physiologic derangements (i.e. volume overload; metabolic acidosis, reten-
tion of uremic toxins, hyperkalemia; hypocalcemia), alterations to coronary vasoreactivity, 
and ventricular remodeling and fibrosis that indirectly exert negative effects on cardiac 
function. AKI may also adversely impact cardiac function by contributing to alternations 
in drug pharmacokinetics and pharmacodynamics. Additional experimental and transla-
Cardiorenal Syndrome Type 3: 
Pathophysiologic and Epidemiologic 
Considerations
Sean M. Bagshaw a  · Eric A. Hoste b  · Branko Braam c  ·  
Carlo Briguori d  · John A. Kellum e  · Peter A. McCullough f  ·  
Claudio Ronco g  · for the Acute Dialysis Quality Initiative 
11 Working Group
a
 Division of Critical Care Medicine, Faculty of Medicine and Dentistry, University of Alberta, 
Edmonton, Alta., Canada; b Department of Critical Care Medicine, University of Gent, Gent, Belgium; 
c
 Division of Nephrology, Departments of Medicine and Physiology, Faculty of Medicine and 
Dentistry, University of Alberta, Edmonton, Alta., Canada; d Department of Cardiology, Clinica 
Mediterranea, Naples, Italy; e Clinical Research, Investigation, and Systems Modeling of Acute Illness 
Center, Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, Pa., USA; f St. John 
Providence Health System, Warren, Mich., Providence Hospitals and Medical Centers, Southfield 
and Novi, Mich., St. John Macomb Oakland Center, Madison Heights, Mich., St. John Hospital and 
Medical Center, Detroit, Mich., USA; g Department of Nephrology Dialysis and Transplantation and 
International Renal Research Institute (IRRIV), San Bortolo Hospital, Vicenza, Italy
ADQI 11 Workshop members are listed in Appendix 2.
D
ow
nl
oa
de
d 
by
: 
Bi
om
ed
isc
he
 B
ib
lio
th
ee
k 
   
   
   
   
   
   
   
   
   
   
 
15
7.
19
3.
76
.8
8 
- 5
/2
9/
20
13
 1
2:
09
:0
6 
PM
McCullough PA, Kellum JA, Mehta RL, Murray PT, Ronco C (eds): ADQI Consensus on AKI Biomarkers and 
Cardiorenal Syndromes. Contrib Nephrol. Basel, Karger, 2013, vol 182, pp 137–157 (DOI: 10.1159/000349971)
138 Bagshaw  et al.
tional investigations coupled with epidemiologic surveys are needed to better explore 
that pathophysiologic mechanisms underpinning acute cardiac events associated with 
AKI and their impact on outcomes. Copyright © 2013 S. Karger AG, Basel
Cardiorenal syndrome (CRS) type 3 (acute renocardiac syndrome) is a subclas-
sification of the CRS whereby an episode of acute kidney injury (AKI) precipi-
tates and contributes to the development of acute cardiac injury and/or dysfunc-
tion [1]. There are a number of potential contributing causes for AKI that may 
predispose to the development of CRS type 3 and which are relevant for the 
susceptibility, etiology, severity and duration of the type 3 CRS (table 1).
In general, there is limited understanding of the pathophysiologic mecha-
nisms whereby AKI contributes to acute cardiac injury and/or dysfunction. An 
episode of AKI may have severity and duration-dependent effects that both di-
rectly and indirectly predispose to an acute cardiac event. There is some experi-
mental data to suggest that cardiac injury may be directly induced by inflamma-
tory mediators, oxidative stress, and upregulation of neuroendocrine systems 
early after AKI [2–5]. Likewise, AKI may be associated with physiologic de-
rangements (i.e. volume overload; metabolic acidosis, retention of uremic tox-
ins, hyperkalemia; hypocalcemia), alterations to coronary vasoreactivity, and 
ventricular remodeling and fibrosis that indirectly exert negative effects on car-
diac function [6–10]. The development of AKI may also adversely impact car-
diac function, through both direct and indirect mechanisms, by contributing to 
alternations in drug pharmacokinetics and pharmacodynamics. The relation-
ship between these direct and indirect mechanisms remains poorly understood.
There is a paucity of data describing the epidemiology of acute cardiac events 
(i.e. arrhythmia, myocardial ischemia, heart failure, cardiac arrest) occurring 
after an episode of AKI. There is also a lack of data specifically describing the 
temporal sequence of cardiac events after onset of AKI, including the dose-re-
sponse effects related to AKI severity and duration on short- and long-term car-
diac function [11, 12]. Moreover, there are challenges when trying to extrapolate 
on the epidemiology of CRS type 3 from the available literature due to: (1) vari-
ability in the methods for defining AKI and heterogeneity in the contributing 
causes for AKI; (2) variability in the populations at risk being studied and their 
susceptibility for development of either AKI or acute cardiac events; (3) diffi-
culty in clarifying the temporal association between AKI and acute cardiac 
events, in particular from observational data, and (4) failure of many observa-
tional studies and clinical trials focused on AKI to specifically capture and/or 
describe the occurrence of acute cardiac events as key outcomes of interest.
Accordingly, the objectives of this review were to: (1) to design a patho-
physiologic model of CRS type 3 supported by evidence; (2) identify from this 
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model descriptive/epidemiological and mechanistic knowledge gaps, and (3) 
provide where possible recommendations for future investigation.
Methods
The 11th Scientific Acute Dialysis Quality Initiative (ADQI) Meeting on Cardio-Renal 
Syndromes assembled experts on this topic, including cardiologists, nephrologists, in-
tensivists, physiologists and epidemiologists [13].
This report is the result of a modified Delphi analysis performed by the ADQI Work-
ing Group [14]. The Delphi method is a structured and standardized process for collect-
ing, summarizing and disseminating knowledge from a group of experts focused on a 
specific problem or task. A detailed description of the ADQI methodology is available at 
www.adqi.net [15]. In brief, the process included pre-meeting, at meeting and post-meet-
ing activities.
Prior to the meeting, each member of the working subgroup on the topic of CRS type 
3 developed a list of preliminary questions and objectives. The key questions were fo-
cused on two broad themes: understanding the pathophysiologic mechanisms and the 
epidemiology of CRS type 3 (table 2).
Each working group member subsequently performed a systematic literature search 
focused around these key questions. The literature search was conducted using the Med-
line database (via the PubMed interface). In general, three broad search themes were 
used: (1) ‘pathophysiology’; (2) ‘acute kidney injury’ and ‘acute renal failure’, and (3) 
‘cardiorenal’, ‘myocardial infarction’, ‘heart failure’, ‘arrhythmia’, and ‘acute coronary 
syndrome’. The bibliographies of identified studies and relevant review articles or edito-
Table 1. Summary of potential contributing causes for AKI 
contributing to CRS type 3
Prototypical condition
Contrast-induced AKI Post-inflammatory GN
Drug-induced AKI Rhabdomyolysis
Major surgery Acute pyelonephritis
Cardiac surgery Post-obstructive uropathy
Table 2. Summary of susceptibilities for CRS type 3
Risk-modifying factors
Age Congestive heart failure
Sex Pulmonary disease
Coronary artery disease Chronic kidney disease
Hypertension Systemic vascular disease
Hypercholesterolemia Systemic immune disease
Diabetes mellitus Infection/sepsis
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rials were also reviewed along with the personal records of each participating member 
for additional potentially relevant studies. This literature was reviewed and evaluated to 
determine the current status of consensus on each of the key questions.
Activities at the meeting, involving the entire working group, included a review of the 
ADQI methodology, a systematic evaluation of the quality of the retrieved evidence, and 
incorporation of evidence-based medicine principles into the review process. If evidence 
on specific key questions was unavailable or lacking, the working subgroup discussed 
how ‘best clinical practice’ would be established. The working subgroup used breakout 
sessions from the main meeting to review, discuss and catalogue the available literature 
and formulate summary statements to describe existing consensus, best practice and 
recommendations for future research. The findings from these working subgroup 
breakout sessions were then presented to the entire ADQI delegate working group at the 
meeting for feedback and suggested revisions. This method was repeated through an it-
erative process until majority consensus was achieved.
Post-meeting activities included compilation of the findings and consensus from the 
meeting and drafting of summary documents.
Findings
Acute Kidney Injury
AKI is common and increasingly encountered in hospitalized patients. The ma-
jority of episodes of severe AKI occur in association with critical illness and are 
supported in an intensive care setting. Susceptibility to development to AKI 
likely stems from numerous interacting factors including genetic predisposition 
[16–19], demographics and burden of comorbid illness such as older age [20], 
cardiovascular disease, diabetes mellitus and chronic kidney disease (CKD), 
coupled with clinical events and/or iatrogenic exposures. In addition, the sever-
ity and duration of AKI correlated with subsequent risk for complications [21, 
22]. However, few data have described the epidemiology of acute cardiac events 
(i.e. arrhythmia, myocardial ischemia, heart failure, cardiac arrest) temporally 
following an episode of AKI, including whether dose-response effects related to 
AKI severity and duration impact short- and long-term risk of cardiac events.
Pathophysiologic Mechanisms of AKI-Induced Cardiac Injury
Direct Mechanisms
AKI is accompanied by almost instantaneous non-hemodynamic events that 
originate in the kidney and have distant organ effects, including the heart [2, 23]. 
The direct physiologic mechanisms by which AKI interacts with the heart have 
been referred to as the ‘cardiorenal connectors’ [24]. These mechanisms encom-
pass, but are not likely limited to activation of the systemic immune system (i.e. 
pro- and anti-inflammatory cytokines and chemokines with alteration in leuko-
cyte trafficking and extravasation); the sympathetic nervous (SNS), renin-angio-
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tensin-aldosterone (RAAS) and coagulation systems; along with increases in 
oxidative stress (i.e. disruption in the balance between radical oxygen species 
and nitric oxide (NO)). For each of these ‘cardiorenal connector’ mechanisms, 
there is limited experimental evidence to support a pathophysiologic role of AKI 
directly mediating cardiac events and/or dysfunction.
The majority of experimental studies evaluating the immune ‘cardiorenal 
connectors’ have focused on renal ischemia and ischemia/reperfusion injury 
(IRI). Accordingly, there is little description of the direct interaction of immune 
response and cardiac performance following AKI in alternative settings (i.e. 
nephrotoxin, post-obstructive, sepsis). In IRI models, AKI has been shown to 
elicit a systemic immune response characterized by dose-response increase in 
circulating levels of pro- and anti-inflammatory mediators. AKI may also 
contribute to functional alterations in immune cell responsiveness and alterations 
to leukocyte trafficking, adhesion and tissue extravasation both locally in the 
kidney and in distal organs such as the heart [2]. Leukocytes have long been 
thought important in cardiac dysfunction following ischemia and blocking 
leukocyte function or localization may protect against injury [25]. Elevated 
white blood cell count is associated with increased risk of acute myocardial 
infarction [26] and removing white blood cells from cardioplegia solution 
improves myocardial function in stressed piglet hearts [27].
Several studies have found circulating levels of tumor necrosis factor-α 
(TNF-α), interleukin (IL)-1 and IL-6 to increase immediately after renal IRI in 
experimental models [3–5, 7, 28, 29]. Several cytokines have now been implicated 
as myocardial depressant substances including TNF-α, IL-1β, IL-6, IL-2, and 
interferon-γ (IFN-α). Elevated TNF-α and IL-6 have been shown to have direct 
cardiodepressant effects, characterized by reduced left ventricular (LV) fraction-
al shortening, and elevated LV end-diastolic and systolic dimensions [2, 3, 24, 30]. 
Cytokines can impact myocardial function due to both impaired myocyte con-
tractility and interaction with the extracellular matrix. In general, cytokine-me-
diated contractile dysfunction is reversible over an extended time period of sev-
eral days following exposure [4]. Although these cytokines typically impart nega-
tive inotropic effects, the nature and pattern of the inotropic response is more 
complex, consisting of an immediate response (within minutes) that can be either 
stimulatory or depressant, depending on the experimental conditions and physi-
ologic milieu, and a delayed response lasting hours to days that is uniformly car-
diodepressant and dependent on the production of secondary mediators [4]. The 
cellular mechanisms underlying these effects are multiple. NO derived from con-
stitutive NO synthase, sphingolipid mediators, arachidonic acid, and alterations 
in intracellular Ca2+ handling have all been shown to contribute to the immediate 
contractile effects, whereas the delayed response results primarily from the com-
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bined influence of NO generated from inducible NOS, the production of radical 
oxygen species and alterations in β-adrenergic receptor signaling [4].
In the isolated rat heart, perfusion with TNF-α results in a decrease in LV 
diastolic pressure and coronary vasoconstriction [31]. Sustained infusion of 
TNF-α causes time-dependent, delayed (2 h to 2 days) contractile dysfunction 
and LV dilatation, that could persist for up to 10 days, depending on the dose 
administered [5]. Reduced LV performance has also been associated with several 
diastolic abnormalities including slowing of relaxation, LV dilatation without 
changes in end-diastolic pressure (myocardial creep), and a leftward shift of the 
end-diastolic pressure-strain relation, indicating increased diastolic stiffness. 
Pressure-volume studies of the isolated, blood-perfused canine heart have 
shown that TNF-α acutely impacts LV mechanoenergetics by increasing the 
oxygen cost of contractility, an effect ascribed to alterations in energy utilization 
for excitation-contraction coupling [32].
Following IRI, rat hearts also exhibit increased expression of intercellular 
adhesion molecule-1, myeloperoxidase and apoptosis [3]. Of interest, only renal 
IRI and not bilateral nephrectomy resulted in a significant increase in myocardial 
apoptosis, implying systemic inflammation rather than acute uremia may play 
a more immediate and direct role in myocardial injury and dysfunction in AKI. 
Moreover, TNF-α likely contributes directly to cardiac myocyte apoptosis, as 
demonstrated by attenuation of apoptosis following administration of anti-
TNF-α antibodies [3].
Increased circulating levels of pro-inflammatory cytokines have been dem-
onstrated in patients with chronic heart failure and are associated with maladap-
tive ventricular remodelling, poor functional status, chronic cachexia and death 
[33]. Two large randomized trials have evaluated of anti-TNF therapies for at-
risk chronic heart failure patients, however while shown to be relatively safe, 
neither were efficacious for reducing mortality [34]. To date, TNF-α inhibition 
following an episode of AKI and its effects are myocardial injury and/or function 
have not yet been evaluated. By extrapolation, this concept may have merit for 
CRS type 3, in settings where moderate to severe AKI induces a strong immune 
response characterized by markedly elevated levels of inflammatory mediators, 
in particular those with direct myocardial effects such as TNF-α. As an example, 
in a folic-acid-induced rat model of AKI, administration of a single low dose of 
cyclosporine A (1–5 mg/kg) not only markedly attenuated development of AKI 
(i.e. rise in serum creatinine, urea) but also attenuated systemic IL-6 expression, 
TNF-like weak inducer of apoptosis (TWEAK) expression, nuclear factor-κB 
activation, inflammatory cell infiltration and renal tubular cell apoptosis when 
compared with controls [35]. Recently, deficiency of heme oxygenase-1, an en-
zyme induced by oxidative stress and responsible for degradation of heme mol-
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ecules, was found to exacerbate induction of systemic IL-6 along with IL-6 
mRNA and downstream signaling effectors in myocardial tissue [28].
Alternatively, milder forms of renal IRI may have a ‘protective’ effect on the 
heart against ischemic injury. In a rat study of brief (15 min) renal artery 
occlusion under hypothermic conditions (30 ° C), Gho et al. [36] found marked 
reductions in myocardium at risk and total area infarction when compared with 
controls, however renal IRI injury was failed to attenuate injury at normothermia. 
The precise mechanisms by which mild renal IRI may protect against downstream 
myocardial ischemia are incompletely understood, however may in part be 
mediated by alterations in sympathetic outflow coupled with upregulation of 
anti-inflammatory mediators and anti-apoptotic responses [36, 37].
There is limited data available describing the role of neuroendocrine activation, 
specifically the SNS and RAAS in the pathophysiologic of CRS type 3. However, 
activation of the SNS is a hallmark of both AKI and acute HF [38]. The enhance-
ment of renal SNS activity and its consequent effect on norepinephrine overflow 
from nerve terminals during AKI [39] may impair myocardial function through 
several mechanisms, including: (1) direct effects of norepinephrine, (2) distur-
bances in myocardial Ca2+ homeostasis, (3) increase in myocardial oxygen de-
mand contributing to susceptibility to endocardial ischemia, (4) cardiac myocyte 
apoptosis mediated through β1-adrenergic receptors stimulation [40], (5) stimula-
tion of α1-adrenergic receptors, contributing to cardiac myocyte hypertrophy, and 
(6) direct activation of the RAAS. Heightened adrenergic drive can stimulate β1-
adrenergic receptors in the juxtaglomerular apparatus of the kidneys contributing 
to reduced renal blood flow and exacerbated release of renin and RAAS activation. 
Maladaptive RAAS activation in AKI contributes to angiotensin II (ANGII) re-
lease, vasoconstriction and further loss of extracellular fluid homeostasis. ANGII 
may redundantly contribute to systemic vasoconstrictor and excessive elevation 
of the systemic vascular resistance. ANGII may also play a direct role in modifying 
myocardial structure and function [41], contribute to cellular hypertrophy, and 
precipitate apoptosis in cardiac myocyte cultures [42]. ANGII is also a potent stim-
ulator of a number of cell signaling pathways including those involved in oxidative 
stress, inflammation, and the regulation of the extracellular matrix [43].
In a dog model of renal IRI, Kingma et al. [8] implied increased activity of 
the RAAS contributing to observed diminished coronary responsiveness to ace-
tylcholine, adenosine, bradykinin, and L-arginine. In addition, renal IRI result-
ed in greater myocardial oxygen consumption at rest. While a definitive role for 
the RAAS was not established, these data imply that AKI may directly contrib-
ute to impaired coronary vasoreactivity and elevated myocardial oxygen con-
sumption that would potentially increase susceptibility to myocardial ischemia 
and major cardiac events. Several rat models of renal IRI have shown increased 
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secondary lung injury due largely to alternation in pulmonary vascular perme-
ability with resultant interstitial edema and alveolar hemorrhage [2]. The al-
tered pulmonary vascular permeability associated with AKI is directly mediated 
by systemic inflammatory mediators and kidney-lung cross-talk. The resulting 
alveolar congestion and edema is in part mediated by altered expression of epi-
thelial sodium channel and aquiporin-5 expression. Similar mechanisms may 
also contribute to myocardial interstitial edema and dysfunction [44]. Trans-
genic sickle mice subjected to renal IRI exhibited significantly increased myo-
cardial capillary congestion, serum amyloid-P (murine equivalent of C-reaction 
protein), and renal expression of caspase-3 compared with controls [45].
In addition, while we considered the cardiac-specific cellular responses as-
sociated with AKI including the role of mitochondrial dysfunction, apoptosis, 
remodelling, and fibrosis, limited data were available. Robinson et al. [46] 
evaluated cardiac mitochondrial function in a rat model of glycerol-induced 
AKI. In this study, isolated heart preparations showed site-unspecific uncoupling 
of oxidative phosphorylation. This contributed to increased mitochondrial Ca2+ 
uptake, and may provide explanation for the diminished inotropic response in 
the setting of AKI.
Cardiac myocyte apoptosis and neutrophil infiltration are important 
contributors to the pathophysiology of myocardial infarction during AKI and 
transgenic models have shown that even apoptosis alone can lead to lethal heart 
failure [3]. In this study, kidney IRI, but not uremia, was critical to induction of 
apoptosis in myocardial tissue. Another experimental model of cisplatin-
induced AKI found an increased number of TUNEL-positive cells implying 
significant myocardial apoptosis [47]. It has been demonstrated that apoptotic 
rates of only 23 cardiac myocytes per 105 nuclei are sufficient to induce a lethal, 
dilated cardiomyopathy [48]. Although this frequency of cell death is quite low, 
it is still 15-fold higher than that observed in healthy human hearts. Decreasing 
intracellular iron levels is also known to induce apoptosis [49].
The strongest evidence of a cardiorenal link between AKI and the development 
of cardiac fibrosis is the β-galactoside-binding lectin galectin-3 [9, 10]. Galectin-3 
mRNA expression in renal tubules was shown to be upregulated early after IRI 
and toxin-induced AKI and persisted for 7 days following injury [9]. Importantly, 
galectin-3 has been implicated in the development of myocardial fibrosis and 
heart failure in an experimental model of AKI [10]. Moreover, inhibition of ga-
lectin-3 can mitigate the formation of cardiac fibrosis [50].
Indirect Mechanisms
The workgroup identified a number of potential consequences of AKI that may 
act to indirectly contribute to reduced cardiac function (fig. 1, 2).
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Volume Overload. Excess fluid accumulation is associated with less favorable 
outcomes in critically ill patients. In a large randomized trial of fluid management 
strategies in critically ill patients with acute lung injury, a conservative fluid regi-
men was associated with improved lung function and a trend for lower utilization 
of renal replacement therapy (RRT) compared with a liberal fluid regimen [51]. 
Similar data have also been shown in critically ill children [52]. Moreover, excess 
fluid accumulation may worsen kidney function through venous congestion and 
AKI
Susceptibility
Severity/
duration
Hypotension
Contrast
Obstruction
Etiology
Direct
Indirect
Outcome
Cellular response (PATHO)Physiological Clinical
Apoptosis
Mitochondrial dysfunction
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Fig. 1. Summary of the demographic contributors, clinical susceptibilities and pathophys-
iologic mechanisms for development of CRS type 3. Reproduced with permission from 
ADQI [88].
Uremic cardiomyopathy
CRS 3 HFHypertension
Preload
Afterload
Contractility
Volume overload
Fig. 2. Summary of the interaction of clinical complications of AKI and theoretical nega-
tive physiologic effects on myocardial performance. Reproduced with permission from 
ADQI [88].
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intra-abdominal hypertension. Several observational studies, while not established 
causality, consistently show association between fluid overload and less favorable 
outcomes in critically ill patients with AKI [53, 54]. In addition, fluid removal in 
these patients, either through loop diuretics use [55] or ultrafiltration [56], was as-
sociated with higher survival. Fluid accumulation may adversely impact myocar-
dial performance [44], predispose to ventricular arrhythmias [57] and may con-
tribute to maladaptive ventricular remodelling and myocardial fibrosis [44, 58].
Hypertension. The majority of critically ill patients with AKI may present with 
hypotension due to the precipitating etiology for AKI (i.e. major surgery, sepsis, 
cardiogenic shock), however beyond the inciting event contributing to CRS type 3, 
a number of mechanisms may contribute to the development of both systemic and 
pulmonary hypertension. This may occur through volume overload contributing 
to elevated preload, alterations in cardiac output and increased afterload through 
total body autoregulation, activation of the SNS and RAAS. In susceptible patients, 
these may contribute to myocardial ischemia, arrhythmias and ventricular dys-
function. Increased activation of the SNS and RAAS has been well described in 
conditions such as hepatorenal syndrome and acute decompensated heart failure 
[59].
Acidemia. Metabolic acidosis is a common complication of AKI. In a recent 
survey of critical care clinicians, 74% of the respondents stated that metabolic 
acidosis was a key factor contributing to a decision to initiate RRT among criti-
cally ill patients [60]. In the RENAL study, a large prospective randomized study 
evaluating the intensity of continuous RRT (CRRT), 35% of critically ill patients 
had severe acidemia at time of initiation of CRRT [61]. The accumulated acid 
(i.e. H+ ions) may alter the protein structure and interfere with normal function. 
This may directly contribute to decreased myocardial contractility through 
changes to β-receptor expression and altered intracellular calcium handling [62].
Hyperkalemia. Similar to acid-base homeostasis, potassium is predominant-
ly dependent on kidney function for elimination from the body. Hyperkalemia 
is a life-threatening complication of AKI and an important absolute indication 
for RRT [60], however studies of patients with severe AKI show hyperkalemia is 
a relatively infrequent reason for RRT initiation [63]. Hyperkalemia is associ-
ated with cardiac toxicity and arrhythmic complications (see below).
Hypophosphatemia. While untreated AKI is often associated with elevated 
plasma phosphate levels, patients started on RRT commonly develop hypophos-
phatemia [61, 64, 65]. Hypophosphatemia may be an unrecognized iatrogenic 
complication associated with respiratory muscle weakness and impaired myo-
cardial performance [66, 67].
Uremic Toxins. In CKD, more than 100 uremic toxins or retention products 
have been identified [68]. Uremic toxins include water-soluble, protein-bound 
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and small molecular weight compounds with variable pharmacodynamic pro-
files. Several uremic toxins (i.e. indoxylsulfate, p-cresol conjugates, β2-
microgliobulin, and FGF-23) are associated with cardiovascular toxicity in CKD 
[69]. However, there is a relative paucity of data on acute uremia in AKI. In AKI, 
uremic compounds may exert different time-dependent physiologic effects 
when compared to those described in CKD. There is indirect evidence to suggest 
uremic compounds in AKI may negatively impact kidney function. For exam-
ple, coronary vasoreactivity is adversely affected in AKI, resulting in altered 
thresholds for myocardial ischemia in conditions of increased myocardial oxy-
gen demand [8]. Uremic toxicity is complicated, as varying duration and sever-
ity of AKI as well as concomitant non-renal organ dysfunctions may synergisti-
cally act to adversely impact cardiac function.
Pathophysiological Effects of AKI on the Heart
The pathophysiologic mechanisms underlying the interplay between kidney in-
jury and heart dysfunction are still not completely understood (fig. 2). However, 
we can summarize several of the physiologic effects whereby AKI may negative-
ly impact heart function as: (a) electrophysiological, (b) ischemic, (c) myocar-
dial and/or (d) pericardial.
Electrophysiological Effects
The loss of acid-base, electrolyte and fluid homeostasis occurring in AKI may 
precipitate alteration in heart rhythm. Electrical signaling in the heart involves 
the passage of ions through ionic channels. The Na+, K+, Ca2+, and Cl– ions are 
the major charge carriers, and their movement across the cell membrane creates 
a flow of current that generates excitation and signals contraction in cardiac 
myocytes.
Hyperkalemia is associated with a distinctive sequence of electrocardiogram 
(ECG) changes. The earliest is usually narrowing and peaking (tenting) of the T 
wave (fig. 3). The ratio of intracellular to extracellular potassium is important 
for determining the cellular membrane potential. Small changes in the extracel-
lular potassium level can have profound effects on the function of the electrical 
conduction system of the heart. In the setting of hyperkalemia, the excess extra-
cellular potassium will increase the activity of the potassium channel, resulting 
in faster repolarization and thus creating the narrow base and tall T wave. On 
the other hand, this will inactivate the sodium channel, preventing proper con-
duction of electrical activity. Progressive extracellular hyperkalemia reduces 
atrial and ventricular resting membrane potentials, thereby inactivating sodium 
channels. Moderate to severe hyperkalemia occasionally induces ST segment 
elevations in the right precordial leads (V1 and V2) and simulates an ischemic 
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a
b
Fig. 3. Hyperkalemia. a A 54-year-old woman with acute renal failure due to glomerulo-
nephritis status was admitted with acute onset of shortness of breath. Her clinical exami-
nation and radiographic findings were consistent with acute pulmonary edema. ECG 
shows normal sinus rhythm with tall T waves best seen in leads V3, V4 and V5. The tall T 
wave is symmetrical, narrow, scooped inwards and ‘tented’. K+ level was 5.8 mEq/l. This 
classic appearance of the T wave is usually associated with hyperkalemia. The PR interval, 
QRS duration and QTc interval are all within normal range. The P wave is wide (>0.12 s in 
duration) and bifid in shape – so-called ‘P-mitrale’ in lead II. There is a negative compo-
nent in lead V1, which is widened and slurred, consistent with left atrial enlargement. 
b ECG shows significant widening of the QRS complex to 158 ms with right bundle branch 
block morphology associated with coved ST segment elevation in lead V1, resembling 
‘Brugada ECG pattern’, which can be seen in severe hyperkalemia. Reproduced with per-
mission from ADQI [88].
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current-to-injury pattern. However, even severe hyperkalemia can be associated 
with atypical or non-diagnostic ECG findings. Hyperkalemia can induce a Bru-
gada-like pattern in the ECG [70]. This usually occurs in critically ill patient with 
significant hyperkalemia (serum [K+] >7.0 mmol/l) and is associated with pseu-
do-right bundle branch block and persistent ST segment elevation in at least two 
precordial leads (fig. 4). Very marked hyperkalemia leads to eventual asystole, 
sometimes preceded by a slow undulatory (sine-wave) ventricular flutter-like 
pattern [71].
Severe hypermagnesemia can cause AV nodal and intraventricular conduc-
tion disturbances that may culminate in complete heart block and cardiac arrest.
An increased extracellular calcium concentration shortens the ventricular ac-
tion potential duration by shortening phase 2 of the action potential. This cel-
lular change correlates with the shortening of the QT interval (ST segment por-
tion). Hypercalcemia may produce a high takeoff of the ST segment in leads V1 
and V2 that can simulate acute ischemia. Ca2+ plays a central role in the regula-
tion of myocardial contraction and relaxation and there is increasing evidence 
that disturbances in Ca2+ handling may play a central role in the disturbed con-
tractile function in heart failure. The intracellular Ca2+ transient demonstrates a 
blunted rise with depolarization, reflecting slower delivery of Ca2+ to the con-
LV
 p
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m
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g)
LV volume (ml) LV volume (ml)
Diastolic
dysfunction
Hypertension/
volume overloadIncreased preload
Hypertension/
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Immune/uremia
Increased afterload
Reduced contractility
a b
Fig. 4. a, b Mechanisms of LV dysfunction in CRS type 3. Reproduced with permission from 
ADQI [88].
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tractile apparatus (causing slower activation) and a slower rate of fall during re-
polarization (causing slower relaxation). These two abnormalities could explain 
both systolic and diastolic dysfunction [72].
Ischemic Effects
The theoretical pathophysiological mechanisms responsible of myocardial isch-
emia during AKI may also include the following: (1) acidemia; (2) neurohor-
monal activation (i.e. SNS and RAAS), and (3) acute accumulation of uremic 
toxins and cytokines [31]. The SNS activation can lead to vasoconstriction and 
increased myocardial oxygen demand. These can lead to ischemia when oxygen 
delivery is restricted, in particular in susceptible patients. TNF-α induces coro-
nary vasoconstriction, which contributes indirectly to contractile dysfunction in 
isolated, crystalloid-perfused rat hearts [73]. Endothelin and bradykinin may be 
also responsible for the reduced vessel function. Endothelin is a potent peptide 
vasoconstrictor released by endothelial cells throughout the circulation. Its re-
lease from endothelial cells can be enhanced by several vasoactive agents (AN-
GII, norepinephrine) and cytokines (TNF, and IL-1β). During AKI, higher levels 
of myocardial oxygen demand would trigger maldistribution of ventricular 
blood flow and result in subendocardial ischemia. It has been demonstrated that 
during AKI (1) coronary autoregulation is preserved but the lower autoregula-
tory break point shifts to a higher coronary perfusion pressure; (2) coronary 
vascular reserve and coronary vascular conductance are markedly diminished, 
and (3) coronary vessel reactivity to either endothelium-dependent or -indepen-
dent vasodilators is substantially reduced [8]. The observed reduction in coro-
nary venous PO2 during AKI may reflect: (1) a reduced bioavailability of NO to 
vascular smooth muscle cells as a result of structural alterations in the vessel or 
microvessel wall, (2) an increased destruction of NO as a result of overproduc-
tion of reactive oxygen intermediates in the vessel wall, and (3) an impaired 
dilatation to NO donors (e.g. nitroglycerin) as a result of defective vascular 
smooth muscle cell function at the level of the soluble guanylate cyclase/cyclic 
guanosine monophosphate signaling pathway [74].
Recent evidence has emerged to implicate a potentially important patho-
physiologic link between neutrophil gelatinase-associated lipocalin (NGAL), a 
25-kDa lipocalin covalently bound to gelatinase from human neutrophils in-
volved inflammation and cellular matrix degradation, and CRSs [75]. NGAL is 
a strong marker of acute renal tubular injury [76]. Renal NGAL expression rap-
idly increased following acute inflammation and/or injured renal tubular epi-
thelia, in particular following damage from IRI and toxin exposure [77]. NGAL 
is also believed to play an important role in iron homeostasis and traffic and may 
activate apoptotic pathways by regulating the intracellular iron concentration 
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[78]. NGAL has also been implicated in the pathophysiology of heart failure, 
myocarditis and in coronary atherosclerosis [79–81]. Likewise, urinary kidney 
injury molecule-1, a specific marker of renal tubular damage, has also been im-
plicated for modifying the susceptibility to heart failure risk [82]. These data 
suggest that acutely upregulated biomarkers of kidney damage, such as NGAL 
and kidney injury molecule-1, may circulate to have distant pathophysiologic 
effects on the heart, including myocardial inflammation, destabilization of ath-
erosclerotic plaques and susceptibility to ischemic events.
Myocardial Effects
In animal experiments, it has been shown that 48 h after kidney IRI, functional 
changes in the myocardium including LV dilatation, increased LV end-diastolic 
and end-systolic diameters, increased relaxation time, and decreased fractional 
shortening are evident [3]. The proposed pathophysiological mechanisms re-
sponsible for LV dysfunction following an episode of AKI include accumulation 
of inflammatory mediators (i.e. cytokines); leukocyte infiltration, SNS activation; 
acute sodium and fluid retention; metabolic acidosis, and accumulation of ure-
mic toxins.
The ventricular pressure-volume loop provides a paradigm to understand the 
relationship between intraventricular pressure and volume throughout the 
cardiac cycle. Figure 4 shows the pressure-volume relationship under normal 
conditions and following development of severe AKI. The combined global 
effect was therefore postulated. The theoretical detrimental effects of AKI on 
myocardial mechanics may include: (1) increase in preload due to intravascular 
fluid accumulation (causes a rightward shift of the LV loop); (2) increase in 
afterload due to increased mean systemic blood pressure (causes an increase in 
LV end-systolic pressure); (3) increase in diastolic dysfunction due to loss of 
calcium homeostasis (causes an upward shift of the LV loop), and (4) increase 
in systolic dysfunction due to inflammatory mediators and uremic toxins (causes 
a reduction in contractility).
Pericardial Effects
Uremia through the myocardial-depressant factors (cytokines) may precipitate 
pericarditis [83].
Clinical Outcomes Associated with CRS Type 3
There is limited data in the literature on the impact of AKI on occurrence of 
cardiac-specific events and outcomes (table 3). However, in a large population-
based cohort study, James et al. [84] evaluated the association of AKI following 
coronary angiography (i.e. CI-AKI) and occurrence of cardiovascular-related 
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hospitalizations, in addition to mortality and end-stage kidney disease (ESKD). 
Increasing severity of CI-AKI was associated with a dose-response increase in 
risk of heart failure hospitalization (AKIN stage I: HR 1.48, 95% CI 1.16–1.91; 
AKIN stage II/III: 2.17, 95% CI 1.49–3.15). Similar patterns were also seen for 
mortality, progression to ESKD and AKI-related hospitalization. Anzai et al. [12] 
prospectively evaluated 141 consecutive patients receiving reperfusion therapy 
after presentation with first anterior ST-elevation myocardial infarction, of which 
22.0% (n = 31) developed AKI within 48 h, defined as an increase in serum cre-
atinine >0.3 mg/dl (26.5 µmol/l). The development of early post-reperfusion AKI 
was independently associated with higher risk for in-hospital cardiac events in-
cluding heart failure, ventricular arrhythmia, and cardiac-specific death, along 
with long-term cardiac events including rehospitalization for heart failure and 
major adverse cardiac events (MACE). Cardiovascular-related deaths are the sec-
ond most common cause of death after sepsis, predominantly attributable to 
heart failure and ischemic cardiac events, in patients with AKI [85].
Table 3. Summary of key questions proposed by the ADQI Working Group
Pathophysiologic mechanisms of CRS type 3
1. What are the most important ‘direct’ pathophysiologic mechanisms following an 
episode of AKI that contribute to cardiac injury/dysfunction?
a. What is the time course (temporality)?
b. What is the impact of etiology, severity and/or duration (dose response)?
2. What are the most important ‘indirect’ pathophysiologic mechanisms following an 
episode of AKI that contribute to cardiac injury/dysfunction?
a. What is the time course (temporality)?
b. What is the impact of etiology, severity and/or duration?
3. What is the relationship between direct and indirect pathophysiologic mechanisms 
on cardiac injury/dysfunction?
a. What is the relationship between cardiac pressure-volume mechanics (i.e. indi-
rect) and myocardial function (i.e. direct) following an episode of AKI?
Epidemiology of CRS type 3
1. What are the important factors modifying the risk/susceptibility for cardiac-specific 
events after an episode of AKI?
a. Baseline susceptibilities kidney and cardiac-specific factors (non-modifiable)?
2. What are the key contributing factors for development of AKI in CRS type 3?
a. What is an ideal representative etiology for AKI to describe the CRS type 3 (i.e. 
contrast-induced nephropathy)
b. What is the role iatrogenesis in CRS type 3?
3. What is the incidence and spectrum of cardiac-specific events following an episode 
of AKI?
4. What is the time course for cardiac-specific events following an episode of AKI? (ESC 
guidelines ~1 month)
5. What are the implications of CRS type 3 on the natural history of cardiac function?
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Consensus Recommendations for Future Research
Future investigations focused on CRS type 3 should surveillance for cardiac-
specific events (table 4) not only during the in-hospital period but also during 
long-term follow-up (i.e. 6–12 months). CRS type 3 may be associated with both 
downstream cardiac and kidney-specific adverse outcomes. In addition to car-
diac-specific events, the occurrence of kidney-specific outcomes, including sub-
sequent episodes of AKI [86], incident CKD, progression to ESKD and MACE 
should be captured. Future investigations should also integrate an assessment of 
baseline susceptibility for cardiac-specific events following development of CRS 
type 3 (i.e. low, intermediate, high) and evaluate how these susceptibilities are 
modified by either the severity of AKI and the duration of AKI. For example, 
risk of a cardiac-specific event associated with AKI may be similar for a patient 
suffering a mild but extended episode of AKI compared with a patient develop-
ing a more severe episode of relative short duration.
Consensus Recommendations for Clinical Practice
Evolving data suggest that surrogate measures of kidney-related damage, such 
as hypertension and proteinuria, may represent simply screening measures to 
predict long-term decrements in kidney function [87].
Conclusions
CRS type 3 represents a poorly understood subgroup of heart-kidney interac-
tion, both with respect to the precise pathophysiologic mechanisms and its epi-
demiology. Additional experimental and translational investigations coupled 
with epidemiologic surveys are needed to better explore that pathophysiologic 
mechanisms underpinning acute cardiac events associated with AKI and their 
impact on outcomes.
Table 4. Summary of cardiac-specific events
Spectrum of outcome events
Heart failure
Myocardial infarction
Ventricular arrhythmia
Major adverse cardiac event (MACE)
Accelerated loss cardiac function
Cardiac surgery
Mechanical support device
Death
Hospitalization
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